The processing technology of Pinellia ternata decoction pieces won the invention patent
Release time:
2023-07-26
The technological innovation project of "Development and Industrialization of Pinellia ternata Based on Alkaline Negative Ion Glycyrrhiza Extract" of Jianfeng Health Technology Company was approved by Jinhua Economic and Information Bureau in November 2022, and was authorized by the national invention patent in July 2023.
Pinellia ternata decoction pieces commonly used in clinical practice of traditional Chinese medicine are dried tubers of Pinellia ternata, a perennial herb of Araceae. The whole plant of Pinellia ternata is toxic, and its tuber can be poisoned when eaten raw at 0.1-1.8g, which has strong stimulation to the mucous membranes of oral cavity, throat and digestive tract. Taking a small amount can make the mouth and tongue numb, while taking a large amount can cause burning pain and swelling, inability to vocalize, vomiting, numbness of the whole body, slow and incomplete breathing, spasm, dyspnea, which can lead to permanent loss and even paralysis to death. Therefore, the common Pinellia ternate on the market is processed. Most of the commonly used processing methods are water, fire or water and fire. The operation steps are complicated, the processing time is long, and the wastewater generated in the processing process is highly toxic, which will cause subsequent pollution and increase the cost of wastewater treatment. In view of this, Jianfeng Health has developed a Pinellia ternata processing technology. By pretreating the net Pinellia ternata, the cell permeability of Pinellia ternata is improved, and then using ginger and alum for detoxification treatment, it can effectively improve the detoxification efficiency, shorten the detoxification time and improve the production efficiency. At the same time, in the process of soaking and detoxification, by applying an electric field to the soaking solution and using alum solution as the electrolyte, on the one hand, the introduction of other heavy metal ions can be avoided, on the other hand, the detoxification efficiency can be accelerated, and the heavy metal content in the wastewater can be reduced. In the process of industrialization, this technology not only greatly shortens the processing time of Pinellia ternata and improves the production efficiency, but also reduces the toxicity of the wastewater after the processing of Pinellia ternata and reduces the cost of wastewater treatment. (Lu Guosheng)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page